Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed the day trading at $25.16 up 1.37% from the previous closing price of $24.82. In other words, the price has increased by $1.37 from its previous closing price. On the day, 0.86 million shares were traded. APLS stock price reached its highest trading level at $25.19 during the session, while it also had its lowest trading level at $24.7359.
Ratios:
For a better understanding of APLS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.48. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
On October 15, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $32.
Goldman Downgraded its Neutral to Sell on September 26, 2025, while the target price for the stock was maintained at $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’25 when Watson David O. sold 5,000 shares for $24.49 per share. The transaction valued at 122,450 led to the insider holds 103,730 shares of the business.
Watson David O. bought 5,000 shares of APLS for $122,450 on Dec 16 ’25. On Nov 17 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $20.06 each. As a result, the insider received 100,300 and left with 108,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 3183374336 and an Enterprise Value of 3178516480. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 84.74. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 7.93. Its current Enterprise Value per Revenue stands at 3.127 whereas that against EBITDA is 38.723.
Stock Price History:
The Beta on a monthly basis for APLS is 0.31, which has changed by -0.23011017 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.57, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is 8.60%, while the 200-Day Moving Average is calculated to be 14.87%.
Shares Statistics:
Over the past 3-months, APLS traded about 2.66M shares per day on average, while over the past 10 days, APLS traded about 2531200 shares per day. A total of 126.50M shares are outstanding, with a floating share count of 103.76M. Insiders hold about 17.99% of the company’s shares, while institutions hold 99.29% stake in the company. Shares short for APLS as of 1765756800 were 17247829 with a Short Ratio of 6.49, compared to 1763078400 on 16349387. Therefore, it implies a Short% of Shares Outstanding of 17247829 and a Short% of Float of 17.940001.
Earnings Estimates
As of right now, 11.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.37 and low estimates of -$0.63.
Analysts are recommending an EPS of between $0.48 and $0.04 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is -$1.16, with 11.0 analysts recommending between -$0.09 and -$1.73.
Revenue Estimates
19 analysts predict $200.44M in revenue for. The current quarter. It ranges from a high estimate of $232.4M to a low estimate of $184.82M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 19 analysts are estimating revenue of $190.89M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $174M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $988.69M, resulting in an average revenue estimate of $1.01B. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $863.98M in the next fiscal year. The high estimate is $955M and the low estimate is $787.62M.
